Dr. Ribas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 Med Plz
Ste 550
Los Angeles, CA 90095- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Universidad de Barcelona Faculty of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 2001 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma Start of enrollment: 2004 Feb 01
- CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Start of enrollment: 2004 Apr 01
- Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy Start of enrollment: 2004 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer.Ciuba, D., Shelach, N., Zelinger, G., Barrow, B., Corn, B., Katz, S., Ribas, A.> ;JAAD International. 2024 Jun 1
- A Spatial Omnibus Test (SPOT) for Spatial Proteomic Data.Sarah Samorodnitsky, Katie Campbell, Michael C Wu, Antoni Ribas> ;Biorxiv. 2024 Mar 13
- Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer.Daniel G Chen, Jingyi Xie, Jongchan Choi, Rachel H Ng, Rongyu Zhang, Sarah Li, Rick Edmark, Hong Zheng, Ben Solomon, Katie M Campbell, Egmidio Medina, Antoni Ribas, Pu...> ;Cell Reports. 2024 Mar 26
- Join now to see all
Journal Articles
- Isolation and Characterization of NY-ESO-1–Specific T Cell Receptors Restricted on Various MHC MoleculesAntoni Ribas, Proceedings of the National Academy of Sciences
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
- Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human CancersAntoni Ribas, Jennifer A Wargo, Sumit K Subudhi, Padmanee Sharma, Clinical Cancer Research
- Join now to see all
Lectures
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients with BRAFV600-Mutated Metastatic MelanomaInternational Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
- International Society for Biological Therapy of Cancer (iSBTc): Annual MeetingInternational Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/26/2012
Authored Content
- Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018
Press Mentions
Melanoma Vaccine Still Showing Promise in Clinical TrialsApril 17th, 2023- mRNA Vaccine for Melanoma Reduces Relapse After Therapy, Trial FindsApril 16th, 2023
- Prior Treatments Influence Immunotherapy Response in Advanced MelanomaApril 10th, 2023
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
